Management of advanced, unresectable hepatocellular carcinoma patients largely rely upon systemic therapy. Considering poor tolerability of sorafenib and promising role of mTOR inhibitors, everolimus could be a potential therapeutic option. A 65 year old, female patient was diagnosed with advanced hepatocellular carcinoma, ineligible to surgery or transplant. Therapy was started with sorafenib but withdrawn due to dermal toxicity. The patient was switched to everolimus which was continued for 17 months. Everolimus was well tolerated and inhibited the disease progression effectively. At follow up patient demonstrated stable disease with no increase in number or size of the cancerous nodules since diagnosis.